Loading Events

« All Events

Mechanisms of Closed-loop SCS: 5 Years of Patient Data

October 21, 2021 (PDT) @ 5:30 pm 6:30 pm PDT

Dr. Eric Grigsby, MD, MBA is Chief Executive Officer and Founder of Neurovations.  For over three decades, Dr. Grigsby has focused his clinical career on academia and private practice. Today, in addition to busy practices, surgery centers, education divisions and labs, Dr. Grigsby guides research and innovation at Neurovations.

Dr Grigsby has been seminally involved in the majority of the interventional devices and therapies used in the field of pain management. He guides start-ups and industry-leading companies through the innovation, discovery and clinical research process which includes access to sites for clinical investigation in pain and neurologic disease. 

The Neurovations Education division holds world-class programs and ACCME accredited conferences in Pain and Neuroscience.  Additionally, Neurovations Education helps companies and clinicians develop and learn surgical therapies.  Dr. Grigsby’s non-profit foundation, HealthRoots, is committed to community health and innovation for underserved patients and communities.

Originally from Knoxville, Tennessee, Dr. Grigsby is a graduate of Brown University with an undergraduate degree in Biology and Economics. He completed medical school at Boston University School of Medicine and residency training in Anesthesiology and Pain Medicine at the Mayo Clinic in Rochester, Minnesota. He received his Master’s in Business Administration in Health Sector Management from Duke University.

John Parker, PhD, Founder and Chief Scientific Officer, founded the Implant Systems team at NICTA that developed the closed loop feedback technology. Dr. Parker has over 20 years of experience in medical devices, including 13 years at Cochlear Limited, where he served in the role of Chief Technology Officer / executive member of the board of directors.

Mr. Schuermann has more than 25 years of healthcare and medical device leadership experience. Prior to serving as President of Saluda, Mr. Schuermann held the role of Chief Business Officer at Avedro, which executed its initial public offering and then was acquired by Glaukos in 2019. Prior to his time at Avedro, he was Vice President and General Manager of Medtronic’s Mechanical Circulatory Support, a newly formed business unit in the Cardiac & Vascular Group. Before Medtronic he was Senior Vice President of Sales and Marketing at HeartWare and held a number of roles at Boston Scientific. Jim started his medical device career at Sherwood-Davis & Geck, a division of American Home Products. Mr. Schuermann holds an MBA degree from Golden Gate University and a BS from the Kelley School of Business at Indiana University.

Lawrence Poree, MD, PhD, MPH began his neuromodulation career as a basic science researcher at UC Berkeley where he investigated the analgesic properties of CNS hormones as part of his doctoral thesis.  He continued his research in neuromodulation at Johns Hopkins University in the department of Biomedical Engineering where he investigated the neural pathways involved in spinal cord stimulation and the sympathetic nervous system.   He decided to apply his research to medical practice and enrolled at Stanford University where he earned his medical degree and completed his residency in anesthesia while continuing to conduct research on the analgesic properties of alpha-2 agonists.  He then completed an interventional pain fellowship at UCSF.  

He founded and served as medical director of a private practice comprehensive pain management clinic for the next 15 years.  During this time, he consulted for various neuromodulation companies in the development of novel neuromodulation devices.  He returned to academia to head the neuromodulation program at the University Of California at San Francisco Pain Management Center. 

For the past 8 years he has served on the North American Neuromodulation Society (NANS) Board of Directors.  He also serves on the California Society of Interventional Pain Physicians and the International Neuromodulation (CASIPP) Board of Directors.